UK MHRA outlines data integrity expectations for pharma industry
This article was originally published in SRA
Executive Summary
The UK's Medicines and Healthcare products Regulatory Agency has issued its first ever guidance on data integrity, which is a fundamental component of a pharmaceutical quality system and ensures that medicines are of the required quality1.
You may also be interested in...
49 PIC/S Inspectorates Test-Drive Data Integrity Guidance
Pharmaceutical Inspection Cooperation Scheme member inspectorates are trying out the most comprehensive manufacturing data integrity guidance yet developed. Issued amid a flurry of guidance from various authorities, it could play a key role in harmonizing regulatory approaches.
UK MHRA Aims To Address "Fundamental Failures" In Data Integrity
The UK MHRA's revised guidance on maintaining the integrity of data throughout the chemical and pharmaceutical development lifecycle is intended to address various shortcomings identified by regulators during inspections.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.